Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12858313 | 0.97 | GBA1 (0.46) | GBA1 | |
| SCHEMBL15926062 | 0.97 | GBA1 (0.46) | GBA1 | |
| SCHEMBL14396734 | 0.81 | GBA1 (0.45) | GBA1 | |
| SCHEMBL28684227 | 0.78 | ALDH1A1 (0.36) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL19794315 | 0.78 | ALDH1A1 (0.36) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL25938686 | 0.74 | SLC2A1 (0.32) | — | |
| SCHEMBL16259327 | 0.73 | SLC2A1 (0.31) | GBA1 | |
| SCHEMBL16587598 | 0.73 | GBA1 (0.60) | GBA1ALDH1A1 | |
| SCHEMBL24205804 | 0.72 | SLC2A1 (0.51) | — | |
| SCHEMBL10820762 | 0.72 | SLC2A1 (0.37) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210361680-A1 | INOSITOL-BASED IMMUNOTHERAPIES | NORMOXYS INC (US) | 2021-11-25 | — | — | US | disclosed |
| EP-3787634-A1 | INOSITOL-BASED IMMUNOTHERAPIES | NormOxys, Inc. (US) | 2021-03-10 | — | — | EP | disclosed |
| US-20160067267-A1 | MYO-INOSITOL TRISPYROPHOSPHATE AS AN ANTI-OBESITY AGENT | NORMOXYS, INC. (US) | 2016-03-10 | — | — | US | disclosed |
| EP-2968617-A1 | MYO-INOSITOL TRISPYROPHOSPHATE AS AN ANTI-OBESITY AGENT | NormOxys, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2015138916-A1 | MYO-INOSITOL TRISPYROPHOSHATE AS AN ANTI-DIABETIC AGENT | NICOLAU YVES CLAUDE (US) | 2015-09-17 | — | — | WO | disclosed |
| WO-2014143939-A1 | MYO-INOSITOL TRISPYROPHOSPHATE AS AN ANTI-OBESITY AGENT | NORMOXYS, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20140171394-A1 | CYCLITOLS AND THEIR DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS | UNIVERSITE DE STRASBOURG (FR) | 2014-06-19 | — | — | US | disclosed |
| US-20140171394-A1 | CYCLITOLS AND THEIR DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS | UNIVERSITE DE STRASBOURG (FR) | 2014-06-19 | — | — | US | disclosed |
| US-20140171394-A1 | CYCLITOLS AND THEIR DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS | UNIVERSITE DE STRASBOURG (FR) | 2014-06-19 | — | — | US | disclosed |
| US-20130190524-A1 | CYCLITOLS AND THEIR DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS | UNIVERSITE DE STRASBOURG (FR) | 2013-07-25 | — | — | US | disclosed |
| US-20130190524-A1 | CYCLITOLS AND THEIR DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS | UNIVERSITE DE STRASBOURG (FR) | 2013-07-25 | — | — | US | disclosed |
| US-20130190524-A1 | CYCLITOLS AND THEIR DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS | UNIVERSITE DE STRASBOURG (FR) | 2013-07-25 | — | — | US | disclosed |
| EP-2111226-A2 | CYCLITOLS AND THEIR DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS | Normoxys, Inc. (US) | 2009-10-28 | — | — | EP | disclosed |
| US-20080200437-A1 | Polyphosphorylated inositol derivatives; allosteric effectors, cell signaling molecule analogs; hypoxia related diseases | UNIVERSITE DE STRASBOURG (FR) | 2008-08-21 | — | — | US | disclosed |
| US-20080200437-A1 | Polyphosphorylated inositol derivatives; allosteric effectors, cell signaling molecule analogs; hypoxia related diseases | UNIVERSITE DE STRASBOURG (FR) | 2008-08-21 | — | — | US | disclosed |
| US-20080200437-A1 | Polyphosphorylated inositol derivatives; allosteric effectors, cell signaling molecule analogs; hypoxia related diseases | UNIVERSITE DE STRASBOURG (FR) | 2008-08-21 | — | — | US | disclosed |
| WO-2008082658-A2 | CYCLITOLS AND THEIR DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS | NORMOXYS, INC. (US) | 2008-07-10 | — | — | WO | disclosed |
| WO-2008082658-A2 | CYCLITOLS AND THEIR DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS | NORMOXYS, INC. (US) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200437-A1 | Polyphosphorylated inositol derivatives; allosteric effectors, cell signaling molecule analogs; hypoxia related diseases | PPIP5K2, IP6K1, IP6K3 | GBA1 1368/4885ALDH1A1 4593/4885SMN1; SMN2 4693/4885 |
| US-20130190524-A1 | CYCLITOLS AND THEIR DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS | PPIP5K2, ITPA, IPMK | GBA1 624/4885ALDH1A1 4412/4885SMN1; SMN2 4681/4885 |
| US-20140171394-A1 | CYCLITOLS AND THEIR DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS | PPIP5K2, ITPA, IPMK | GBA1 624/4885ALDH1A1 4412/4885SMN1; SMN2 4681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.